<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39403255</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2081-3856</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Translational neuroscience</Title><ISOAbbreviation>Transl Neurosci</ISOAbbreviation></Journal><ArticleTitle>Long COVID elevated MMP-9 and release from microglia by SARS-CoV-2 Spike protein.</ArticleTitle><Pagination><StartPage>20220352</StartPage><MedlinePgn>20220352</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20220352</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1515/tnsci-2022-0352</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Long COVID is a major health concern because many patients develop chronic neuropsychiatric symptoms, but the precise pathogenesis is unknown. Matrix metalloproteinase-9 (MMP-9) can disrupt neuronal connectivity and be elevated in patients with long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this study, MMP-9 was measured in the serum of long COVID patients and healthy controls, as well as in the supernatant fluid of cultured human microglia cell line stimulated by recombinant severe acute respiratory syndrome coronavirus 2 Spike protein, as well as lipopolysaccharide (LPS) and neurotensin (NT) used as positive controls. MMP-9 was measured by commercial enzyme-linked immunosorbent assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">MMP-9 was significantly elevated in the serum of long COVID patients compared to healthy controls. Moreover, there was significant release of MMP-9 from a cultured human microglia cell line stimulated by LPS, NT, or Spike protein. We further show that pretreatment with the flavonoids luteolin and tetramethoxyluteolin (methlut) significantly inhibited the release of MMP-9 stimulated by the Spike protein.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">MMP-9 from Spike protein-stimulated microglia could contribute to the development of long COVID and may serve as a target for treatment including the use of luteolin.</AbstractText><CopyrightInformation>&#xa9; 2024 the author(s), published by De Gruyter.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kempuraj</LastName><ForeName>Duraisamy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Neuro-Immune Medicine (INIM), Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, 33328, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsilioni</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, Boston, MA, 02111, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aenlle</LastName><ForeName>Kristina K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Institute for Neuro-Immune Medicine (INIM), Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, 33328, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Miami Veterans Affairs (VA) Geriatric Research Education and Clinical Center (GRECC), Miami Veterans Affairs Healthcare System, Miami, FL, 33125, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimas</LastName><ForeName>Nancy G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Institute for Neuro-Immune Medicine (INIM), Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, 33328, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Miami Veterans Affairs (VA) Geriatric Research Education and Clinical Center (GRECC), Miami Veterans Affairs Healthcare System, Miami, FL, 33125, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theoharides</LastName><ForeName>Theoharis C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Institute for Neuro-Immune Medicine (INIM), Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, 33328, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Miami Veterans Affairs (VA) Geriatric Research Education and Clinical Center (GRECC), Miami Veterans Affairs Healthcare System, Miami, FL, 33125, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, Boston, MA, 02111, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Transl Neurosci</MedlineTA><NlmUniqueID>101550327</NlmUniqueID><ISSNLinking>2081-6936</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MMP-9</Keyword><Keyword MajorTopicYN="N">brain inflammation</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">luteolin</Keyword><Keyword MajorTopicYN="N">mast cells</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>Conflict of interest: Authors state no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39403255</ArticleId><ArticleId IdType="pmc">PMC11472557</ArticleId><ArticleId IdType="doi">10.1515/tnsci-2022-0352</ArticleId><ArticleId IdType="pii">tnsci-2022-0352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Phillips S, Williams MA. Confronting our next national health disaster &#x2013; long-haul covid. N Engl J Med. 2021;385(7):577&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34192429</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Farias L, Saboya MF, Ponte Fernandes N, Perdigao Neto LV, de Arruda EAG. Development of H51Y and E157Q mutations for integrase inhibitor resistance in a patient undergoing treatment for pulmonary tuberculosis: a case report. SAGE Open Med Case Rep. 2023;11:2050313X231220786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10752045</ArticleId><ArticleId IdType="pubmed">38152686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali ST, Kang AK, Patel TR, Clark JR, Perez-Giraldo GS, Orban ZS, et al. Evolution of neurologic symptoms in non-hospitalized COVID-19 &#x201c;long haulers&#x201d;. Ann Clin Transl Neurol. 2022;9(7):950&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9268866</ArticleId><ArticleId IdType="pubmed">35607826</ArticleId></ArticleIdList></Reference><Reference><Citation>Almulla AF, Al-Hakeim HK. Editorial: Neuropsychiatric and neurodegenerative aspects of acute and long COVID. Front Mol Neurosci. 2023;16:1343930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10751905</ArticleId><ArticleId IdType="pubmed">38152586</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanley JE, Valenciano AF, Timmons G, Miner AE, Kakarla V, Rempe T, et al. Longitudinal evaluation of neurologic-post acute sequelae SARS-CoV-2 infection symptoms. Ann Clin Transl Neurol. 2022;9(7):995&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9268882</ArticleId><ArticleId IdType="pubmed">35702954</ArticleId></ArticleIdList></Reference><Reference><Citation>Meshkat S, Salimi A, Joshaghanian A, Sedighi S, Sedighi S, Aghamollaii V. Chronic neurological diseases and COVID-19: associations and considerations. Transl Neurosci. 2020;11(1):294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712023</ArticleId><ArticleId IdType="pubmed">33335769</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24(2):168&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodagar A, Javed R, Tahir H, Razak SIA, Shakir M, Naeem M, et al. Pathological features and neuroinflammatory mechanisms of SARS-CoV-2 in the brain and potential therapeutic approaches. Biomolecules. 2022;12(7):971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9313047</ArticleId><ArticleId IdType="pubmed">35883527</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay ME, Madore C, Tian L, Verkhratsky A. Editorial: Role of neuroinflammation in the neuropsychiatric and neurological aspects of COVID-19. Front Cell Neurosci. 2022;16:840121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863733</ArticleId><ArticleId IdType="pubmed">35221927</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, et al. Microvascular injury in the brains of patients with covid-19. N Engl J Med. 2021;384(5):481&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetto V, Pasetto L, Lisi I, Carbonara M, Zangari R, Ferrari E, et al. Markers of blood&#x2013;brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. Front Immunol. 2022;13:1070379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9798841</ArticleId><ArticleId IdType="pubmed">36591311</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingaropoli MA, Iannetta M, Piermatteo L, Pasculli P, Latronico T, Mazzuti L, et al. Neuro-axonal damage and alteration of blood-brain barrier integrity in COVID-19 patients. Cells. 2022;11(16):2480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9406414</ArticleId><ArticleId IdType="pubmed">36010557</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595(7868):565&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Wang H, Jiang S, Teng J, Zhou D, Chen Z, et al. Brain pathology in COVID-19: clinical manifestations and potential mechanisms. Neurosci Bull. 2024;40(3):383&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10912108</ArticleId><ArticleId IdType="pubmed">37715924</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X, Wang S, Zhang W, Li C, Guo L, Wang Z, et al. Probing long COVID through a proteomic lens: a comprehensive two-year longitudinal cohort study of hospitalised survivors. EBioMedicine. 2023;98:104851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10660018</ArticleId><ArticleId IdType="pubmed">37924708</ArticleId></ArticleIdList></Reference><Reference><Citation>Rempe RG, Hartz AM, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab. 2016;36(9):1481&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5012524</ArticleId><ArticleId IdType="pubmed">27323783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Navarro ER, Gutierrez J. Metalloproteinases and their inhibitors in neurological disease. Naunyn Schmiedebergs Arch Pharmacol. 2022;395(1):27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">34851449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaczmarek KT, Protokowicz K, Kaczmarek L. Matrix metalloproteinase-9: a magic drug target in neuropsychiatry? J Neurochem. 2023. 10.1111/jnc.15976</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15976</ArticleId><ArticleId IdType="pubmed">37791997</ArticleId></ArticleIdList></Reference><Reference><Citation>Beroun A, Mitra S, Michaluk P, Pijet B, Stefaniuk M, Kaczmarek L. MMPs in learning and memory and neuropsychiatric disorders. Cell Mol Life Sci. 2019;76(16):3207&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647627</ArticleId><ArticleId IdType="pubmed">31172215</ArticleId></ArticleIdList></Reference><Reference><Citation>Stawarski M, Stefaniuk M, Wlodarczyk J. Matrix metalloproteinase-9 involvement in the structural plasticity of dendritic spines. Front Neuroanat. 2014;8:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4091410</ArticleId><ArticleId IdType="pubmed">25071472</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanda S, Sandhir R. Blood&#x2013;brain barrier permeability is exacerbated in experimental model of hepatic encephalopathy via MMP-9 activation and downregulation of tight junction proteins. Mol Neurobiol. 2018;55(5):3642&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">28523565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding L, Guo H, Zhang C, Jin H, Guo X, Li T. Elevated matrix metalloproteinase&#x2011;9 expression is associated with COVID&#x2011;19 severity: a meta&#x2011;analysis. Exp Ther Med. 2023;26(6):545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10623216</ArticleId><ArticleId IdType="pubmed">37928509</ArticleId></ArticleIdList></Reference><Reference><Citation>Savic G, Stevanovic I, Mihajlovic D, Jurisevic M, Gajovic N, Jovanovic I, et al. MMP-9/BDNF ratio predicts more severe COVID-19 outcomes. Int J Med Sci. 2022;19(13):1903&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9682503</ArticleId><ArticleId IdType="pubmed">36438922</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnell LN, Clifton J, Natkin LW, Hitt JR, Littenberg B. The association of self-perceived changes due to COVID-19 with mental and physical health among adult primary care patients with multiple chronic conditions: a US-based longitudinal study. J Multimorb Comorb. 2024;14:26335565231222148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10798126</ArticleId><ArticleId IdType="pubmed">38250744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueland T, Holter JC, Holten AR, Muller KE, Lind A, Bekken GK, et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect. 2020;81(3):e41&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320854</ArticleId><ArticleId IdType="pubmed">32603675</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilioni I, Theoharides TC. Recombinant SARS-CoV-2 spike protein and its receptor binding domain stimulate release of different pro-inflammatory mediators via activation of distinct receptors on human microglia cells. Mol Neurobiol. 2023;60(11):6704&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">37477768</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong GU, Lyu J, Kim KD, Chung YC, Yoon GY, Lee S, et al. SARS-CoV-2 infection of microglia elicits proinflammatory activation and apoptotic cell death. Microbiol Spectr. 2022;10(3):e0109122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9241873</ArticleId><ArticleId IdType="pubmed">35510852</ArticleId></ArticleIdList></Reference><Reference><Citation>Olajide OA, Iwuanyanwu VU, Adegbola OD, Al-Hindawi AA. SARS-CoV-2 spike glycoprotein S1 induces neuroinflammation in BV-2 microglia. Mol Neurobiol. 2022;59(1):445&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8551352</ArticleId><ArticleId IdType="pubmed">34709564</ArticleId></ArticleIdList></Reference><Reference><Citation>Samudyata N, Oliveira AO, Malwade S, Rufino de Sousa N, Goparaju SK, Gracias J, et al. SARS-CoV-2 promotes microglial synapse elimination in human brain organoids. Mol Psychiatry. 2022;27:3939&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9533278</ArticleId><ArticleId IdType="pubmed">36198765</ArticleId></ArticleIdList></Reference><Reference><Citation>Placantonakis DG, Aguero-Rosenfeld M, Flaifel A, Colavito J, Inglima K, Zagzag D, et al. SARS-CoV-2 is not detected in the cerebrospinal fluid of encephalopathic COVID-19 patients. Front Neurol. 2020;11:587384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7759491</ArticleId><ArticleId IdType="pubmed">33362695</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur KT, Miller EH, Glendinning MD, Al-Dalahmah O, Banu MA, Boehme AK, et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021;144(9):2696&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083258</ArticleId><ArticleId IdType="pubmed">33856027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis A, Frontera J, Placantonakis DG, Galetta S, Balcer L, Melmed KR. Cerebrospinal fluid from COVID-19 patients with olfactory/gustatory dysfunction: a review. Clin Neurol Neurosurg. 2021;207:106760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8196517</ArticleId><ArticleId IdType="pubmed">34146842</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Kempuraj D. Role of SARS-CoV-2 spike-protein-induced activation of microglia and mast cells in the pathogenesis of neuro-COVID. Cells. 2023;12(5):688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10001285</ArticleId><ArticleId IdType="pubmed">36899824</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, Lutgehetmann M, Hagel C, Sperhake JP, Schroder AS, Edler C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey R, Bishayi B. Microglial inflammatory responses to SARS-CoV-2 infection: a comprehensive review. Cell Mol Neurobiol. 2023;44(1):2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11407175</ArticleId><ArticleId IdType="pubmed">38099973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wierzba-Bobrowicz T, Krajewski P, Tarka S, Acewicz A, Felczak P, St&#x119;pie&#x144; T, et al. Neuropathological analysis of the brains of fifty-two patients with COVID-19. Folia Neuropathol. 2021;59(3):219&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">34628787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachiller S, Jimenez-Ferrer I, Paulus A, Yang Y, Swanberg M, Deierborg T, et al. Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response. Front Cell Neurosci. 2018;12:488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6305407</ArticleId><ArticleId IdType="pubmed">30618635</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L, El KJ. Microglia in neurodegeneration. NatNeurosci. 2018;21(10):1359&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol. 2021;12:746021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V, Mahajan A, Spikes L, Krishnamachary B, Ram AK, Kumar A, et al. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol. 2023;95(2):e28568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10048846</ArticleId><ArticleId IdType="pubmed">36756925</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, Henrich TJ, Lu S, et al. SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19. Ann Neurol. 2022;91(6):772&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76(3):e487&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis A, Frontera J, Placantonakis DG, Lighter J, Galetta S, Balcer L, et al. Cerebrospinal fluid in COVID-19: a systematic review of the literature. J Neurol Sci. 2021;421:117316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833669</ArticleId><ArticleId IdType="pubmed">33561753</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, Bach K, Boribong BP, Buggert M, et al. Author correction: SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol. 2023;24(10):1778.</Citation><ArticleIdList><ArticleId IdType="pubmed">37723351</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong Z, Mai H, Kapoor S, Puelles VG, Czogalla J, Sch&#xe4;dler J, et al. SARS-CoV-2 spike protein accumulation in the skull-meninges brain axis: potential implications for long-term neurological complications in post-COVID-19. bioRxiv. 2023. 10.1101/2023.04.04.535604</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.04.535604</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AB, Tsilioni I, Leeman SE, Theoharides TC. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci U S A. 2016;113(45):E7049&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111711</ArticleId><ArticleId IdType="pubmed">27663735</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. Biofactors. 2021;47(2):232&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250989</ArticleId><ArticleId IdType="pubmed">33847020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JJ, Korm S, Kim WS, Kim OS, Lee JS, Min HG, et al. Nobiletin suppresses MMP-9 expression through modulation of p38 MAPK activity in human dermal fibrobalsts. Biol Pharm Bull. 2014;37(1):158&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">24389490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamiya T, Mizuno N, Hayashi K, Otsuka T, Haba M, Abe N, et al. Methoxylated flavones from Casimiroa edulis La Llave suppress MMP9 expression via inhibition of the JAK/STAT3 pathway and TNF alpha-dependent pathways. J Agric Food Chem. 2024;72(26):14678&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">38910321</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliara V, De Rosa M, Di Donato P, Nasso R, D&#x2019;Errico A, Cammarota F, et al. Inhibition of interleukin-6-induced matrix metalloproteinase-2 expression and invasive ability of lemon peel polyphenol extract in human primary colon cancer cells. Molecules. 2021;26(23):7076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8658805</ArticleId><ArticleId IdType="pubmed">34885656</ArticleId></ArticleIdList></Reference><Reference><Citation>Milton-Laskibar I, Trepiana J, Macarulla MT, Gomez-Zorita S, Arellano-Garcia L, Fernandez-Quintela A, et al. Potential usefulness of mediterranean diet polyphenols against COVID-19-induced inflammation: a review of the current knowledge. J Physiol Biochem. 2023;79(2):371&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9641689</ArticleId><ArticleId IdType="pubmed">36346507</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MT, Jang NH, Lee HJ. Natural products as regulators against matrix metalloproteinases for the treatment of cancer. Biomedicines. 2024;12(4):794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11048580</ArticleId><ArticleId IdType="pubmed">38672151</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhao W. Resveratrol alleviates ischemic brain injury by inhibiting the activation of pro-inflammatory microglia via the CD147/MMP-9 pathway. J Stroke Cerebrovasc Dis. 2022;31(4):106307.</Citation><ArticleIdList><ArticleId IdType="pubmed">35093629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn JN, Kaushik DK, Mishra MK, Wang J, Silva C, Yong VW. Impact of minocycline on extracellular matrix metalloproteinase inducer, a factor implicated in multiple sclerosis immunopathogenesis. J Immunol. 2016;197(10):3850&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">27733550</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo MA, Wen TH, Binder DK, Ethell IM, Razak KA. Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9. Behav Brain Res. 2019;372:112068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6662633</ArticleId><ArticleId IdType="pubmed">31271818</ArticleId></ArticleIdList></Reference><Reference><Citation>Tras B, Eser Faki H, Ozdemir Kutahya Z, Bahcivan E, Dik B, Uney K. The effects of dexamethasone and minocycline alone and combined with N-acetylcysteine and vitamin E on serum matrix metalloproteinase-9 and coenzyme Q10 levels in aflatoxin B1 administered rats. Pol J Vet Sci. 2022;25(3):419&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">36156107</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeli S, Zahmatkesh M, Ansari Dezfouli M. Simvastatin attenuates hippocampal MMP-9 expression in the streptozotocin-induced cognitive impairment. Iran Biomed J. 2019;23(4):262&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6462290</ArticleId><ArticleId IdType="pubmed">30218997</ArticleId></ArticleIdList></Reference><Reference><Citation>Naji MT, Al-Kuraishy HM, Al-Gareeb AI. Differential effects of statins on matrix metalloproteinase-9 (MMP-9) in patients with acute ischaemic stroke: a potential for salutary. J Pak Med Assoc. 2021;71(12):S82&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35130225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunny A, James RR, Menon SR, Rayaroth S, Daniel A, Thompson NA, et al. Matrix Metalloproteinase-9 inhibitors as therapeutic drugs for traumatic brain injury. Neurochem Int. 2024;172:105642.</Citation><ArticleIdList><ArticleId IdType="pubmed">38008261</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SL, Halvorsen B, Holter JC, Huse C, Tveita A, Troseid M, et al. Circulating markers of extracellular matrix remodelling in severe COVID-19 patients. J Intern Med. 2023;294(6):784&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">37718572</ArticleId></ArticleIdList></Reference><Reference><Citation>Vafadari B, Salamian A, Kaczmarek L. MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. J Neurochem. 2016;139(Suppl 2):91&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">26525923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimata M, Ishizaki M, Tanaka H, Nagai H, Inagaki N. Production of matrix metalloproteinases in human cultured mast cells: involvement of protein kinase C-mitogen activated protein kinase kinase-extracellular signal-regulated kinase pathway. Allergol Int. 2006;55(1):67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">17075289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>